U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-QSB



(Mark One)



[ x ]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the quarterly period ended:

September 30, 2004



[    ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES

EXCHANGE ACT OF 1934



For the transition period from

to





Commission file number 000-49833



ACRONGENOMICS

(Exact name of small business issuer as specified in its charter)



|NEVADA                                                         | 52-2219285                       
|-------------------------------------------------------------- | ---------------------------------
|(State or other jurisdiction of
incorporation or organization) | (IRS Employer
Identification No.)



1530 9thAvenue, S.E.

Calgary, Alberta, Canada, T2G-0T7

(Address of principal executive offices)



Telephone: (403 693-8014

(Issuers telephone number)



Not applicable

(Former name, former address and former fiscal year, if changed since last report)



Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.



Yes  X

No  _____



APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court

Yes

No _____



APPLICABLE ONLY TO CORPORATE ISSUERS



State the number of shares outstanding of each of the issuers classes of common equity, as of the last practicable date:



15,077,000shares of common stock, $.001 par value, as of November 11, 2004.



Transitional Small Business Disclosure Format (check one):

Yes

No  X









PART I FINANCIAL INFORMATION



ITEM 1.  FINANCIAL STATEMENTS



The accompanying unaudited condensed financial statements set forth at the end of the quarterly report, starting on page F-1, have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-QSB and Rule 10-01 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.  In the opinion of management, all adjustments considered necessary for a fair presentation have been included.  All such adjustments are of a normal recurring nature.  Operating results for the three month periods ended September 30, 2004 and 2003 are not necessarily indicative of the results that may be expected for the year ending December 31, 2004.  For further information refer to the consolidated financial statements and footnotes thereto included in the Companys Annual Report on Form 10-KSB for the year ended December 31, 2003.



|                                                    | Page     
|--------------------------------------------------- | ---------
|                                                    |          
|Interim Consolidated Balance Sheet                  | F-2      
|                                                    |          
|Interim Consolidated Statements of Loss and Deficit | F-3      
|                                                    |          
|Interim Consolidated Statements of Cash Flows       | F-4      
|                                                    |          
|Notes to Interim Financial Statements               | F-5  F-7







ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



CONSOLIDATED

FINANCIAL STATEMENTS

(Unaudited)

AS AT SEPTEMBER 30, 2004

(Stated in U.S. Dollars)

F-1



ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



CONSOLIDATED

BALANCE SHEET

(Unaudited)

AS AT SEPTEMBER 30, 2004

(Stated in U.S. Dollars)



ASSETS



Sept 30,

Dec 31,

2004

2003



CURRENT ASSETS

Cash

$

13,386

$

23,274

Accounts and Trust Receivable

11,472

-

Prepaid Expenses

-

110

24,858

23,384



CAPITAL ASSETS (Note 4)

28,493

-



PATENT(Note 5)

600,000

-



$

653,351

$

23,384



LIABILITIES AND SHAREHOLDERS EQUITY



CURRENT LIABILITIES

Accounts Payable

$

31,925

$

2,275



LONG TERM LIABILITES

Due to Shareholder

134,526

-

166,451

2,275



SHAREHOLDERS EQUITY

Share Capital

Authorized Capital

100,000,000 Common Shares, par value of $0.001 per share

Issued and Outstanding:

14,635,000 Common Shares at September 30/04 & 10,115,000 at

December 31/03

14,635

10,115

Warrants

370,307

-

Additional Paid-In Capital

943,058

67,885

Deficit Accumulated During the Development Stage

(841,100)

(56,891)

486,900

21,109



$

653,351

$

23,384

F-2



ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)

CONSOLIDATED

STATEMENT OF LOSS

(Unaudited)

FOR THE NINE (9) MONTHS ENDED SEPTEMBER 30, 2004

(Stated in U.S. Dollars)

|                                                 |                    |                   |                |              | INCEPTION    
|------------------------------------------------ | ------------------ | ----------------- | -------------- | ------------ | -------------
|                                                 | THREE MONTHS ENDED | NINE MONTHS ENDED | AUGUST 17     
|                                                 | SEPTEMBER 30       | SEPTEMBER 30      | 1999 TO       
|                                                 | 2004               | 2003              | 2004           | 2003         | SEPT 30,2004 
|                                                 |                    |                   |                |              |              
|EXPENSES                                         |                    |                   |                |              |              
|Personnel                                        |                    |                   |                |              |              
|Commissions                                      | -                  | -                 | 35,000         | -            | 35,000       
|Consulting Fees                                  | 36,197             | -                 | 58,528         | 2,147        | 63,876       
|                                                 | 36,197             | -                 | 93,528         | 2,147        | 98,876       
|Facility                                         |                    |                   |                |              |              
|Rent                                             | 4,000              | -                 | 8,000          | -            | 8,000        
|Equipment Repair & Maintenance                   | -                  | -                 | 161            | -            | 161          
|Utilities                                        | 1,054              | -                 | 2,934          | -            | 2,934        
|Telephone                                        | -                  | -                 | 4,118          | -            | 4,118        
|Licence and Fees                                 | -                  | -                 | 2,215          | -            | 2,215        
|                                                 | 5,054              | -                 | 17,428         | -            | 17,428       
|Development                                      |                    |                   |                |              |              
|Appraisals                                       | 10,000             | -                 | 10,000         | -            | 10,000       
|Domain Registration                              | -                  | -                 | 142            | 110          | 282          
|Transfer Agent/Dues                              | 541                | -                 | 6,571          | 50           | 7,931        
|Website Development                              | -                  | -                 | -              | -            | 4,750        
|Public Relations                                 | 113,428            | -                 | 171,460        | -            | 171,460      
|Patents and Trademarks                           | 335                | -                 | 680            | -            | 680          
|Research Expense                                 | 351,900            | -                 | 351,900        | -            | 351,900      
|                                                 | 476,204            | -                 | 540,753        | 160          | 547,003      
|General and Administration                       |                    |                   |                |              |              
|Professional Fees                                | 34,869             | 1,173             | 94,397         | 8,545        | 131,809      
|Travel                                           | 1,593              | -                 | 24,754         | -            | 24,754       
|Bank Charges/Interest                            | 363                | -                 | 812            | -            | 812          
|Office and Sundry                                | 911                | 3,824             | 7,448          | 6,240        | 17,101       
|Advertising                                      | -                  | -                 | 55             | -            | 55           
|Delivery                                         | -                  | -                 | 127            | -            | 127          
|Miscellaneous                                    | -                  | -                 | 1,741          | -            | 1,741        
|Amortization                                     | 1,583              | -                 | 3,166          | -            | 3,166        
|                                                 | 39,319             | 4,997             | 132,500        | 14,785       | 179,565      
|                                                 |                    |                   |                |              |              
|                                                 | 556,774            | 4,997             | 784,209        | 17,092       | 842,872      
|                                                 |                    |                   |                |              |              
|Net (Loss) for the Period, Before the following: | (556,774)          | (4,997)           | (784,209)      | (17,092)     | (842,872)    
|Interest Income                                  | -                  | -                 | -              | 694          | 1,772        
|                                                 |                    |                   |                |              |              
|Net (Loss) for the Period                        | $      (556,774)   | $    (4,997)      | $    (784,209) | $   (16,398) | $   (841,100)
|                                                 |                    |                   |                |              |              
|Net (Loss) Per Share,Basic and Diluted           | (.04)              | (.01)             | (.06)          | (.01)        |              
|                                                 |                    |                   |                |              |              
|Weighted Average Number of Shares Outstanding    | 14,610,000         | 10,115,000        | 12,785,145     | 10,115,000   |              



F-3





|                                                         
|---------------------------------------------------------
|ACRONGENOMICS, INC.                                      
|(Formerly Cellway Ventures Inc.)                         
|(A Development Stage Company)                            
|CONSOLIDATED                                             
|STATEMENT OF CASH FLOWS                                  
|(Unaudited)                                              
|FOR THE NINE (9) MONTHS ENDED SEPTEMBER 30, 2004 AND 2003
|(Stated in U.S. Dollars)                                 
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|CASH FLOW FROM OPERATING ACTIVITIES                      
|Net Loss for the Period                                  
|Amortization                                             
|                                                         
|ADJUSTMENTS TO RECONCILE NET LOSS                        
|TO CASH USED BY OPERATING ACTIVITIES                     
|Change in Accounts & Trusts Receivable                   
|Change in Accounts Payable                               
|Change in Prepaid Expenses                               
|                                                         
|                                                         
|                                                         
|CASH FLOW FROM INVESTING ACTIVITIES                      
|Purchase of Capital Assets                               
|                                                         
|CASH FLOW FROM FINANCING ACTIVITIES                      
|Share Capital and Warrants                               
|Advances from Shareholder                                
|                                                         
|                                                         
|                                                         
|INCREASE (DECREASE) IN CASH                              
|                                                         
|CASH,Beginning of Period                                 
|                                                         
|CASH, End of Period                                      
|                                                         
|                                                         
|                                                         





F-4



ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

SEPTEMBER 30, 2004

(Stated in U.S. Dollars)



1.

BASIC OF PRESENTATION





The unaudited financial statements as of September 30, 2004 included herein have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with United States generally accepted principles have been condensed or molded pursuant to such rules and regulations.  In the opinion of management, all adjustments (consisting or normal recurring accruals) considered necessary for a fair presentation have been included.  It is suggested that these financial statements be read in conjunction with the December 31, 2003 audited financial statements and notes thereto.





2.

NATURE OF OPERATIONS





a)

Organization





The Company was incorporated in the State of Nevada, U.S.A. on August 17, 1999.





b)

Development Stage Activities



The Company plans to acquire and commercialize proprietary technology in the bio-medical industry.  It plans to offer these products in Europe, Canada, the U.S. and other countries throughout the world.



The Company is in the development stage, therefore, recovery of its assets is dependent upon future events, the outcome of which is indeterminable.  In addition, successful completion of the Company's development program and its transition, ultimately to the attainment of profitable operations is dependent upon obtaining adequate financing to fulfill its development activities and achieve a level of sales adequate to support its cost structure.



c)

Going Concern



Since inception, the Company has suffered recurring losses and net cash outflows from operations.  The Company expects to continue to incur substantial losses to complete the development of its business.  Since its inception, the Company has funded operations through common stock issuances in order to meet its strategic objectives.  Management intends to raise additional funds through private placements and warrants being exercised in order to fund working capital requirements.  However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of and, if successful, to commence the sale of its products under development.  As a result of the foregoing, there exists substantial doubt about the Company's ability to continue as a going concern.  These financial statements do not include any adjustments that might result from the outcome of this uncertainty.



3.

SIGNIFICANT ACCOUNTING POLICIES





The consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States.  Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements for a period necessarily involves the use of estimates, which have been made using careful judgment.



The financial statements are consolidated, as they include the financial results of the Company's subsidiary, Acrongenomics Hellas S.A. Inc.

F-5









The financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below:



a)

Development Stage Company





The Company is a developed stage company as defined in the Statements of Financial Accounting Standards No. 7.  The Company is devoting substantially all of its present efforts to establish a new business and none of its planned principal operations have commenced.  All losses accumulated since inception have been considered as part of the Company's development stage activities.



b)

Use of Estimates



The preparation of financial statements in conformity with generally accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses for the reporting period.  Actual results could differ from these estimates.



c)

Income Taxes





The Company has adopted Statement of Financial Accounting Standards No. 109 - "Accounting for Income Taxes" (SFAS 109).  This standard requires the use of an asset and liability approach for financial accounting and reporting on income taxes.  If it is more likely than not that some portion or all if a deferred tax asset will not be realized, a valuation allowance is recognized.



d)

Financial Instruments





The Company's financial instruments consist of cash, accounts payable and amounts due to shareholder. Unless otherwise noted, it is management's opinion that this Company is not exposed to significant interest or credit risks arising from these financial instruments.  The fair value of these financial instruments approximate their carrying values, unless otherwise noted.



e)

Foreign Currency Translation





The Company's functional currency is the U.S. dollar.  Transactions in foreign currencies are converted to U.S. dollars at the rate of exchange prevailing at the time of the transactions.  Exchange gains and losses arising from the re-measurement of foreign currency-denominated assets and liabilities are included in income in the period in which they occur.



f)

Basic and Diluted Loss Per Share





In accordance with SFAS No. 128 - "Earnings Per Share", the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding.  Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.  At September 30, 2004, the Company has no stock equivalents that were anti-dilutive.



a)

Investment in Subsidiary Company





Acrongenomics, Inc. incorporated a subsidiary known as Acrongenomcics Hellas S.A. located in Greece in May 2004.  These financials include the operations of the company and its subsidiary company from the date of incorporation.





F-6





1.

CAPITAL ASSETS



|                 |        |              | 2004       | 2003      
|---------------- | ------ | ------------ | ---------- | ----------
|                 |        | ACCUMULATED  | NET        | NET       
|                 | COST   | AMORTIZATION | BOOK VALUE | BOOK VALUE
|                 |        |              |            |           
|Office Furniture | 31,659 | 3,166        | 28,493     | -         



Amortization of office furniture is calculated on the straight-line basis over the estimated useful life of five (5) years.







5.

PATENT





The Company finalized the acquisition of a certain patent and three (3) patent applications, which it had began negotiating at the beginning of the year.



Such intellectual property was acquired by the issuance of 4,000,000 restricted shares of the Companys common stock.  The intellectual property and all associated rights provide the Company with highly predictive, metastic cancer molecular diagnostic test products and in particular a marketable product known as the Neo EP-CAM Detection Kit.



The cost of the intellectual property has been reported in the financial statements at $600,000, based on the average price of the shares trading at the beginning of the year when negotiations began and allowing for an 80% discount due to the trading restrictions imposed on the shares.



4,000,000 shares @ .15 =

600,000





6.

SHARE CAPITAL



As at September 30, 2004, the company has warrants outstanding as follows:



|WARRANTS    | EXERCISE | DATE         
|----------- | -------- | -------------
|OUTSTANDING | PRICE    | OF EXPIRATION
|            |          |              
|420,000     | $ 1.00   | May 7, 2007  
|420,000     | $ 1.20   | May 7, 2007  
|100,000     | $ 2.30   | Sept 7, 2006 
|            |          |              
|940,000     |          |              
|            |          |              



F-7





ITEM 2.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION.



PLAN OF OPERATION



Acrongenomics, Inc. (the Company), is maintaining a steady course according to its business plan during the last nine (9) months.



The Company believes that it is making substantial progress in the transformation of existing product EP-CAM Detection Kit TM, for the detection of epithelial cancer, to a new commercial application for the global molecular diagnostic market as a result of the agreement for laboratory and scientific consulting services that it entered into with Eurogenet Labs Inc.



Eurogenet Labs Inc., is a Greek company located in Athens, Greece with related shareholders.  Acrongenomics, Inc. paid Eurogenet Labs Inc. $ 351,900 during the quarter ended September 30, 2004 for expenses incurred on behalf of the Company for scientific research, which research has generated the progress in the development of the Company product using.



Nanobiotechnology is a fusion of physical science, biology, molecular engineering, chemistry and biotechnology.  The field of nanobiotechnology is beginning to generate substantial new insights into how biological systems function and holds much promise of advance in pharmaceuticals and health care alike.



Acrongenomics, Inc., already believes that it has a valuable and marketable product known as the Neo EP-CAM Detection Kit, and combined with its research in the nanobiotechnology field, the Company will be well positioned to become an important partner for large companies able to market and distribute our product and benefit from our potential research.





RESULTS OF OPERATIONS



The Company earned no revenue during the quarter or the nine (9) months ended September 30, 2004.  Acrongenomics, Inc. is still in the development stage and does not anticipate earning any revenues until such time as it can establish an alliance with targeted companies to market and distribute our product, the Neo EP-CAM Detection Kit.



The Company incurred operating expenses in the amount of $ 784,209 for the nine (9) months ended September 30, 2004 compared with expenses of $ 17,092 for the same period from the previous year.  The operating expenses of $784,209 incurred during the nine (9) months period included $ 93,528 for personnel, $ 17,428 for facilities such as rent, telephone and utilities, $ 540,753 for research and development and $ 132,500 for general and administration expenses such as professional fees, travel and office supplies.  The substantial increase in operating expenses during the nine months ended September 30, 2004 over the same period for the previous year from $17,092 to $784,209 were mainly as a result of expenditures to establish a scientific research laboratory in the amount of $351,900 and $ 171,460 for public relations to attract potential investors and provide public exposure for the Company.  The increase amount spent on professional fees, travel, facilities and general administrative fees was the result of the Company implementation of its business plan and operational activities.



1



FINANCIAL CONDITION AND LIQUIDITY



The Company had cash on hand as at September 30, 2004, of $ 13, 386 and working capital deficit of $ 7,067, compared to $ 23,274 of cash and $ 21,109 of working capital as at December 31, 2003, respectively.  During the quarter, the Company raised cash from the sale of 100,000 shares in a private placement at $ 2.30 per share, for gross proceeds of $ 230,000.  However, this amount was used to pay the expenses incurred during the quarter.



The Company has reduced its budgeted requirements from $ 3,000,000 to $ 2,500,000 for the next twelve (12) months by reducing the administrative expenses and public relations costs.



Acrongenomics, Inc. presently has 940,000 outstanding warrants with an exercisable value of $ 1,130,000.  Our present cash reserves are not sufficient to meet our cash requirements for the next twelve months. We are working on obtaining additional financing to meet our current needs as well as maintaining our course of action regarding our business plan.



The Company is working on raising additional funds through private placements and potential exercising of outstanding warrants.  If we are successful in completing an equity financing, existing shareholders will experience a dilution of their interest in the Company.  In the event we are not successful in obtaining such financing when necessary, we may not be able to proceed with implementation of all our proposed projects in our business plan.





ITEM 3.

CONTROLS AND PROCEDURES



As required by Rule 13a-15 under the Securities Exchange Act of 1934 (the Exchange Act), we carried out an evaluation of the effectiveness of the design and operation of our disclosure and procedures as at September 30, 2004 being the date of our most recently completed fiscal quarter.  This evaluation was carried out under the supervision and participation of Mr. Rick Walchuk, who at the time was our Chief Executive Officer, till his resignation as CEO effective August 10, 2004 and Ron Lizée our Chief Financial Officer.



Based upon the aforementioned evaluation, Mr. Rick Walchuk and Mr. Ron Lizée concluded that the Companys internal control over financial reporting are effective in timely alerting management to material information relating to the Company required to be included in our periodic SEC filings.  There have been no significant changes in our internal control over financial reporting or in other factors that have materially affected or is reasonably likely to materially affect our internal control over financial reporting.



Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commissions rules and forms.  Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.



2



PART II  OTHER INFORMATION



ITEM 1.  LEGAL PROCEEDINGS



We are not a party to any material legal proceedings and to our knowledge, no such proceedings are threatened or contemplated.



ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS



During the fiscal quarter ended September 30, 2004, we sold the following unregistered shares of our common stock:



On September 7, 2004, we accepted subscriptions totaling $230,000, for which we issued 100,000 units, with each individual unit consisting of one (1) share of our common stock, and a purchase warrant to purchase one (1) additional share of common stock for $ 2.30.  The warrant has a term of two (2) years.



The sale of securities described in the immediately preceding paragraph was exempt from registration due to the exemptions found in Regulation S (Reg S), promulgated by the Securities and Exchange Commission under the Securities Act of 1933.  Acrongenomics paid no commissions or finders fees in connection with the sale of the units.  These securities were issued in offshore transactions since the offerees were not in the United States and the purchasers were outside the United States at the time of the purchase.  Moreover, there were no directed selling efforts of any kind made in the United States.  All documents used in connection with the offers and sales of the securities offshore included statements to the effect that the securities have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States or to U.S. persons unless the securities are registered under the Act or an exemption there from is available and that no hedging transactions involving those securities may not be conducted unless in compliance with the Act.  The offshore subscriber certified that he is not a U.S. person and is not acquiring the securities for the account or benefit of any U.S. person and agreed to resell such securities only in accordance with the provisions of Regulation S, pursuant to registration under the Act or pursuant to an available exemption from registration.  The securities sold are restricted securities and the certificates representing these shares have been affixed with a standard restrictive legend, which states that the securities cannot be sold without registration under the Securities Act of 1933 or an exemption there from and the Company is required to refuse to register any transfer that does not comply with such requirements.



ITEM 3.  DEFAULTS UPON SENIOR SECURITIES



None



ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS



No matters were submitted to our security holders for a vote during the fiscal quarter ended September 30, 2004.



ITEM 5.  OTHER INFORMATION



As previously reported in quarterly report on Form 10-QSB for the period ended June 30, 2004, the Company appointed Mr. Constantine Poulios as a member of its Board of Directors and also named him as a Vice President of the Company.  Mr. Poulios is an attorney licensed and practicing in Athens, Greece.  Mr. Poulios has been a tax and corporate advisor with Ernst & Young since 1997.  Mr. Poulios has a law degree from National University of Athens and a LLM degree from Northwestern University Law School.



On August 10, 2004, Mr. Rick Walchuk resigned as CEO and a member of the Board of Directors and Mr. W. Scott Lawler resigned as a member of the Board of Directors.  Mr. Walchuk will continue fulfilling a vital role for the Company in the area of investor relations and financing.  Mr. Lawler will continue to serve as the Companys U.S. legal counsel.

3





The Company has recently created a Scientific Advisory Board to assist, aid and advise the Board of Directors regarding scientific and technologic matters that relate to or impact on the Companys business.  The initial members of the Scientific Advisory Board are as follows; Dr. Leftheris Georgakopoulos, Prof. Alexandre Vamvakidis, Prof. Teri Boulikas and Mr. Plato Tzouvalis.



ITEM 6.  EXHIBITS



|Exhibit
Number | Description of Exhibit                                                  
|-------------- | ------------------------------------------------------------------------
|3.1            | Articles of Incorporation (1)                                           
|3.2            | Bylaws, as amended (1)                                                  
|4.1            | Share Certificate (1)                                                   
|10.1           | Patent and asset Acquisition Agreement (2)                              
|31.1           | Rule 13a  14(a) Certification of President(3)                          
|31.2           | Rule 13a  14(a) Certification of Chief Financial Officer (3)           
|32.1           | Section 1350  Certification of President and Chief Financial Officer (3)





(1)

Previously filed with the Securities and Exchange Commission as an exhibit to the Registrants Form 10-SB originally filed May 24, 2002, as amended.



(2)

Previously filed as an Exhibit to the June 30, 2004 Quarterly Report on Form 10-QSB.



(3)

Filed as an Exhibit to this Quarterly Report on Form 10-QSB.



4





SIGNATURES



In accordance with the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.





ACRONGENOMICS, INC.



Date:  November 11, 2004



By:         /s/ LEFTHERIS GEORGAKOPOULOS



Name:   LEFTHERIS GEORGAKOPOULOS

Title:     President





By:          /s/ RON LIZÉE



Name:

RON LIZÉE

Title:

Chief Financial Officer

5